medigraphic.com
ISSN 2007-6800 (Impreso)

2020, Número S1

<< Anterior

Rev Mex Traspl 2020; 9 (S1)


Trasplante renal en el receptor del virus de la hepatitis C positivo

García-Juárez I

Idioma: Español
Referencias bibliográficas: 20
Paginas: 127-131
Archivo PDF: 201.43 Kb.


FRAGMENTO

La infección por virus de la hepatitis C (VHC) es, por lo general, asintomática. Para su tamizaje, se requiere de una prueba que evalúe la presencia de anticuerpos del VHC. Para el caso de la enfermedad renal, se ha evaluado el circuito interno de la máquina de hemodiálisis, y se considera que es un contribuidor menor para la transmisión del VHC en pacientes con hemodiálisis. Uno de los mayores factores para su transmisión se ha asociado con la contaminación cruzada del material y de las superficies por la falta de adherencia a los procedimientos de control de infecciones. Por ello, se recomienda realizar una prueba para VHC en aquellos pacientes con reciente diagnóstico de enfermedad renal.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Burra P, Rodríguez-Castro KI, Marchini F, Bonfante L, Furian L, Ferrarese A et al. Hepatitis C virus infection in end-stage renal disease and kidney transplantation. Transpl Int. 2014; 27: 877-891.

  2. Pol S, Parlati L, Jadoul M. Hepatitis C virus and the kidney. Nat Rev Nephrol. 2019; 15: 73-86.

  3. Pawlotsky JM, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G et al. EASL recommendations on treatment of hepatitis c 2018. J Hepatol. 2018; 69: 461-511.

  4. Kim SM, Song IH. Hepatitis C virus infection in chronic kidney disease: paradigm shift in management. Korean J Intern Med. 2018; 33: 670-678.

  5. Joglekar K, Eason JD, Molnar MZ. Do we really need more evidence to use hepatitis C positive donor kidney more liberally? Clin Kidney J. 2017; 10: 560-563.

  6. Salvadori M, Tsalouchos A. Hepatitis C and renal transplantation in era of new antiviral agents. World J Transplant. 2018; 8: 84-96.

  7. Cohen JB, Eddinger KC, Shelton B, Locke JE, Forde KA, Sawinski D. Effect of kidney donor hepatitis C virus serostatus on renal transplant recipient and allograft outcomes. Clin Kidney J. 2017; 10: 564-572.

  8. Fernandes AR, Laranjinha IJ, Birne R, Matias P, Jorge C, Adragão T et al. HCV-infected renal transplant recipients: our experience before the availability of new antiviral drugs. Int J Organ Transplant Med. 2017; 8 (2): 104-109.

  9. Conti F, Serra C, Vukotic R, Felicani C, Mazzotta E, Gitto S et al. Assessment of liver fibrosis with elastography point quantification vs other noninvasive methods. Clin Gastroenterol Hepatol. 2019; 17: 510-517.

  10. Buckley AJ, Thomas EL, Lessan N, Trovato FM, Trovato GM, Taylor-Robinson SD. Non-alcoholic fatty liver disease: Relationship with cardiovascular risk markers and clinical endpoints. Diabetes Res Clin Pract. 2018; 144: 144-152.

  11. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015; 63: 237-264.

  12. Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2017; 15: 11-20.

  13. Sawinski D, Wyatt CM, Locke JE. Expanding the use of hepatitis C-viremic kidney donors. Kidney Int. 2017; 92: 1031-1033.

  14. Kadatz M, Klarenbach S, Gill J, Gill JS. Cost-effectiveness of using kidneys from hepatitis C nucleic acid test-positive donors for transplantation in hepatitis C-negative recipients. Am J Transplant. 2018; 18: 2457-2464.

  15. Durand CM, Bowring MG, Brown DM, Chattergoon MA, Massaccesi G, Bair N et al. Direct-acting antiviral prophylaxis in kidney transplantation from hepatitis C virus–infected donors to noninfected recipients: an open-label nonrandomized trial. Ann Intern Med. 2018; 168: 533.

  16. Prasad N, Patel M, Pandey A, Jaiswal A, Bhadauria D, Kaul A et al. Direct-acting antiviral agents in hepatitis C virus-infected renal allograft recipients: treatment and outcome experience from single center. Indian J Nephrol. 2018; 28: 220.

  17. Aiza Haddad I, Ballesteros Amozurrutia A, Borjas Almaguer OD, Castillo Barradas M, Castro Narro G, Chávez Tapia N et al. Consenso Mexicano para el tratamiento de la hepatitis C. Revista de Gastroenterología de México. 2018; 83 (3): 275-324.

  18. Gupta G, Zhang Y, Carroll NV, Sterling RK. Cost-effectiveness of hepatitis C-positive donor kidney transplantation for hepatitis C-negative recipients with concomitant direct-acting antiviral therapy. Am J Transplant. 2018; 18: 2496-505.

  19. Sibulesky L, Kling CE, Blosser C, Johnson CK, Limaye AP, Bakthavatsalam R et al. Are we underestimating the quality of aviremic hepatitis C-positive kidneys? Time to reconsider. Am J Transplant. 2018; 18: 2465-2472.

  20. Gallegos-Orozco JF, Kim R, Thiesset HF, Hatch J, Lynch K, Chaly Jr T et al. Early results of pilot study using hepatitis C virus (HCV) positive kidneys to transplant HCV infected patients with end-stage renal disease allowing for successful interferon-free direct acting antiviral therapy after transplantation. Cureus. 2016; 8 (11): e890.




2020     |     www.medigraphic.com